trending Market Intelligence /marketintelligence/en/news-insights/trending/nHgSD4pILD8rPvTbb0A1cg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Oragenics plans common stock offering to fund research, clinical trials

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Oragenics plans common stock offering to fund research, clinical trials

Oragenics Inc. started an underwritten public offering of common shares and warrants to buy common shares.

The underwriter will have an option to buy additional common shares and warrants at the public offering price.

Tampa, Fla.-based Oragenics plans to use net proceeds to fund research of its drug candidate AG013, a potential treatment for oral mucositis in cancer patients. Oral mucositis, or mouth sores, are a common complication of cancer treatments.

Proceeds will also be used for clinical trials and preclinical development of the company's lantibiotics program, and for working capital and general corporate purposes.

H.C. Wainwright & Co. is the sole book-running manager for the offering.